Early Toxicity Testing Market

Global Early Toxicity Testing Market Size (2021 to 2026):

As per our report, the global early toxicity testing market size was worth USD 894.54 million in 2021. This figure is forecasted to be growing at a CAGR of 7.88% and worth USD 1307.09 million by 2026.

Toxicity is the degree of the menace posed by a substance to the living organism. The effects of chemical substances on the existing body are studied to select a possible drug candidate during the development of the newer molecule. The toxicity testing was carried out to decide the amount and type of drug such as alcohol, cocaine, amphetamine, barbiturates, benzodiazepine present in the blood cell. Poisonous quality is a good explanation behind the disappointment of medication development and the dismissal of medication advancement. It is a result of measurements, half-life, and different measurements of medication.

MARKET DRIVERS:

Growing demand for early toxicity testing and technological developments in the R & D primarily escalates early toxicity testing market growth.

Preclinical studies that are well-designed and conducted are essential to the success of any drug development program. The growing requirement of detecting toxicity at early stages is boosting the Early Toxicity testing market. Also, owing to the increase in R&D activities and the rise in strict regulatory bodies concerned with public healthcare welfare, the worldwide early toxicity testing market is likely to develop significantly over the projected period. An increase in the use of in vitro models in the early toxicity testing sector throughout the world and an increase in early toxicity testing all contribute to the market's growth. In vivo testing, in vitro testing, and silicon testing is three common toxicity testing procedures. Test animals are used in in vivo testing to carry out the intended testing process. Acute in vivo testing (short-term testing) and chronic in vivo testing are two types of in vivo testing (long-term testing).

Furthermore, this market's long-term growth trends may be captured by maintaining constant process improvements and financial stability to invest in the best strategies. Furthermore, technical developments in vitro methodology, an increase in the use of in vitro models in the global early toxicity testing sector, and an increase in early toxicity testing in various sectors contribute to the market's growth. Leading players worldwide concentrate their efforts on technical developments to increase efficiency, which is more likely to increase market growth. During the projected period, technological improvements in early toxicity testing will create opportunities for the early toxicity testing market to grow. 

MARKET RESTRAINTS:

However, limitations associated with preclinical testing hamper the global early toxicity testing market growth. Moreover, companies perform early toxicity testing to comply with the government standards to market the drug, which is considered one of the growth restraining factors. Lack of awareness about the application of early toxicity is the major growth decline factor. 

Impact of COVID-19 on the global early toxicity testing market:

The sudden outbreak of covid-19 has rapidly increased the demand for the Early toxicity testing market. Toxicity testing determines if a material is toxic to a living or non-living creature. Early toxicity testing is the process of evaluating the amount of tissue or cell damage and the optimal safe dose of any chemical or medicine. Scientists have developed two new medications to prevent COVID-19 infection and treat those exposed to the novel coronavirus. The peptide-based therapies produced by experts at Australia's QIMR Berghofer Medical Research Institute being evaluated in hamsters at IDMIT, a preclinical and clinical research institution in France. The first peptide-based medicine would be administered before viral exposure to assist improve vaccination effectiveness. In contrast, the second treatment would halt the virus from spreading in already infected cells. The discovery of the peptide-based medicines was made possible after the researchers uncovered a previously unknown mode of entry that SARS-CoV-2, the virus that causes COVID-19, exploits to invade cells and cause COVID-19 disease. 

REPORT COVERAGE:

This research report on the global early toxicity testing market has been segmented and sub-segmented into the following categories and analyzed market size and forecast until 2026.

Early Toxicity Testing Market - By Technique:

• In-Vitro
  • Carcinogenicity
  • Dermal toxicity
  • Skin sensitization and irritation
  • Systemic toxicity
  • Ocular toxicity
  • Neurotoxicity
  • Organ toxicity
  • Genotoxicity
• In-Vivo
• In-Silico

Based on the technique, the in-vitro segment was the leader in 2019. This segment held a market share of 70.0% last year and is estimated to remain its supremacy during the forecast period due to system circulation. It is the most preferred method in drug distribution.

The in-Silico segment is expected to have a healthy growth rate during the forecast period following the in-vitro segment. The growth is attributed due to an increase in the obtainment of the benefits provided by the technique. Another factor fueling the In-Silico segment is the adoption of computer-based techniques in diagnostic centers and laboratories.

Early Toxicity Testing Market - By Assays:

• Cell-Based ELISA
• Western Blots
• Enzyme Toxicity Assays
• Receptor Binding Assays
• Bacterial Toxicity Assays
• Tissues Culture Assays

Based on the Assays analysis, cell-based Elisa is estimated to lead the market during the forecast period. These assays do not mandatorily eliminate clinical trials but rather support human experimentation less of a gamble.

Early Toxicity Testing Market - By End User:

• Pharmaceutical
• Food and beverages
• Chemical industry
• Diagnostics
• Cosmetics

Based on the end-user, the pharmaceutical segment will show strong growth during the forecast period. The growth is associated with factors such as increase fondness for in-vitro testing in this pharmaceuticals industry.

The cosmetic segment is considered to have the fastest growth over the analysis period. The increase is due to factors like growing aesthetic consciousness, increasing disposable income across the globe, new product launches in cosmetics, and strict government guidelines to monitor the nature of chemicals used in the products.

Early Toxicity Testing Market - By Region:

• North America
• Europe
• Asia Pacific
• Latin America
• The Middle East and Africa

Regionally, the North American region is expected to have the most significant revenue, followed by Europe during the forecast period. The growth in this region is attributed to the rise in the healthcare infrastructure, favorable government funds in the healthcare sector, and large pharmaceutical companies in this region.  

The European market is expected to have a robust growth rate from 2020 to 2025. Germany is the leading nation in the European region. The growth of this region is based on factors like increasing awareness and favorable policies from the government.

However, Asia-Pacific is expected to have the highest CAGR in the coming years owing to the rise in disposable income and growing demographics. The growth is due to rising efforts for new pharmaceuticals molecules and the acquisition of new technologies to make better quality products. Countries like China and India are majorly contributing to the market growth. Also, the growing research and development of toxic tests to develop new cell assay methods enhance the market's demand.

Latin America is expected to have steady growth during the period. The growth of this region is caused due to increasing awareness of regulatory authorities and advanced technologies accelerating market growth.

The Middle East & Africa region is expected to slow growth over the early toxicity testing market over the period. The rising demand for better treatment procedures is to fuel market growth.

KEY MARKET PARTICIPANTS:

Some notable companies dominating the global early toxicity testing market profiled in this report are Covance, Thermo Fisher Scientific, Quest Diagnostics Corporation, Agilent Technologies, Sigma Aldrich, BD Biosciences, Bio-Rad, Gene Logic, Accelrys, and Charles River Laboratories.

RECENT MARKET DEVELOPMENTS:

• Global Credit Research February 03, 2021, New York — Moody's Investors Service has reviewed the ratings of Quest Diagnostics Incorporated and other ratings related to the same analytical unit. Moody's examined the adequacy of the ratings in the light of the applicable primary methodology, recent developments and comparing the financial and operating characteristics to similarly rated peers at a portfolio review discussion on February 01, 2021.
• In February 2018, Charles River Laboratories Inc., an American company specializing in preclinical and clinical laboratory-acquired MPI research with a transaction of USD 800 million.